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 •  Feline hyperadrenocorticism is much less frequently reported in cats than in dogs and 
consequently treatment protocols are less well established. 
•  Mitotane, ketoconazole and metyrapone have all been used in cats with variable 
success, but the treatment of choice remains bilateral adrenalectomy. 
•  Trilostane, an inhibitor of steroid synthesis that has been used to control 
hyperadrenocorticism in dogs, may provide an alternative for medical management of 
feline hyperadrenocorticism, particularly in cases where severe debilitation makes 
surgery more hazardous. 
 
A seven and a half year old, neutered male domestic short-haired cat was referred to the 
Queen Mother Hospital for Animals, Royal Veterinary College because of a history of 
chronic suppurative skin infections and recurrent abscessation, particularly over the 
hocks.  Dermatological problems had begun approximately 3-4 months prior to referral.  
The owners reported polyuria and polydipsia and a voracious appetite over the past 
month.  The cat had gained some weight (weight at time of referral 7.2kg [15.8lb]) and 
had developed a pendulous abdomen.  The remainder of the coat had become unkempt.  
A large, ulcerated area, which was resistant to healing, had developed between the 
scapulae.  Treatment prior to referral had included multiple courses of antibiotics but the 
response to treatment had been poor.  Blood work had been performed two months ago at 
which time the cat had shown a mild hyperglycaemia (221mg/dl, reference range 68-
126mg/dl ) and had a mild elevation in alanine aminotransferase (199U/l, reference range 
58-150U/l) and a marked increase in serum globulin (68g/l, reference range 26-51g/l). 
 
At the time of referral the cat was dull and depressed.  His coat was poor and seborrhoeic 
and there was alopecia of the nose, ventral abdomen and hindlimbs.  He had a plantigrade 
stance and large,  (sagging? soft?)abscesses covered the accessory tarsal bones 
bilaterally, extending proximally and distally down the hind limbs.  There was bilateral 
popliteal lymphadenopathy.  The cat was reluctant to move and had a low, crouching gait 
with instability of the right hock that led to a gait abnormality.  He had generalised 
muscle wasting and thin skin with multiple skin tears around his neck and shoulders, some of which had merged to form large ulcerated areas.  There was palpable 
hepatomegaly but no other abdominal abnormalities.  
 
We performed a complete blood count and biochemistry panel, along with thoracic and 
abdominal radiographs and abdominal ultrasound.  An ACTH-stimulation test
a was 
carried out and urine was collected for analysis. Considerable skin bruising developed 
around the jugular venopuncture site.  Swabs for bacterial culture were taken from the 
hock abscesses.  Blood results showed a neutrophilia (14.09 x10
9/l, reference range 2.5-
12.5 x10
9/l) and lymphopenia (0.16 x10
9/l, reference range 1.5-7.0 x10
9/l), minor 
increases in amylase (1475U/l, reference range 750-1200U/l), lipase (354U/l, reference 
range 0-90U/l) and alkaline phosphatase (170U/l, reference range 35-140U/l), and 
hyperglycaemia (437mg/dl, range 68-126mg/dl).  Alanine aminotransferase was within 
reference ranges.  The urine had a specific gravity of 1.032, 3+ glucose, 2+ protein, 2+ 
blood and abundant yeast cells were found in the urine sediment.  Culture of the urine 
yielded a pure growth of Candida albicans.  Radiography revealed hepatomegaly.  
Abdominal ultrasonography identified both adrenal glands greater than 7mm in 
dorsoventral width.  The liver had a diffusely increased echogenicity.  ACTH-stimulation 
test
a results revealed a basal cortisol of 197nmol/l rising to 307nmol/l 60 minutes and 
354nmol/l 120 minutes after administration of ACTH
a.  Bacterial culture of the pus from 
the hock abscesses yielded a mixed growth of bacteria including Escherichia coli and 
Klebsiella species that were sensitive to enrofloxacin and ampicillin respectively. 
 
Although the clinical signs and history were suggestive of pituitary-dependent 
hyperadrenocorticism with secondary diabetes mellitus, the ACTH-stimulation test that 
we performed was not conclusively diagnostic.  The cat’s owners declined further 
invasive testing, however, nor were they able to cover the cost of a magnetic resonance 
scan to identify a possible pituitary tumour.  The cat remained hospitalised for 7 days and 
the hock abscesses were drained, bathed and flushed with sterile saline twice daily. 
Treatment was started with protamine zinc insulin
b (2IU, s/q, q 24 hrs) as well as 
ampicillin
c (20mg/kg [9.1mg/lb] PO q 8 hrs) and enrofloxacin
d (2.5mg/kg [0.1mg/lb] PO, 
q 12 hrs for two weeks) to resolve the skin infections.  We also began treatment with the steroid synthesis inhibitor trilostane
e (30mg, PO, q 24 hrs.) with a view to monitoring the 
cat’s response to this drug and reaching a presumptive diagnosis through a positive 
response to treatment.  No specific treatment for the funguria was given as it was hoped 
that this would be cleared once the diabetes and hyperadrenocorticism were under 
control.  An ACTH-stimulation test
a was repeated before the cat was discharged from the 
hospital. A summary of the ACTH-stimulation test
a results from this (day 7) and 
subsequent examinations is shown in Table 1. 
 
Two weeks later the owners reported an improvement in the cat’s general demeanour and 
activity levels. His appetite for water and food had decreased, though he was still eating 
well.  The hock lesions had partially resolved and though the skin tears between the 
scapulae were still ulcerated, they were cleaner and showed signs of re-epithelialisation. 
A biochemistry profile, urine analysis, total T4 measurement and ACTH-stimulation test
a 
were repeated (Table 1, day 21).  Biochemical parameters were all within normal limits.  
The T4 was slightly low at 18.6nmol/l (range 19-65nmol/l).  Urine analysis, including 
sediment examination, was unremarkable. A 24-hour glucose curve showed that although 
the initial response to insulin was good and the glucose nadir 7-8mmol/l (3.8-7.0mmol/l), 
the insulin was not lasting 24 hours and the glucose had risen to 21.8mmol/l (3.8-7.0) by 
the following morning.  On the basis of these results the daily insulin dose was split into 
two doses of 1IU, to be given twelve hours apart. 
 
Although the cat improved clinically on trilostane
e, and the diabetes was well controlled, 
the skin lesions around the cat’s neck persisted and we decided to increase the trilostane 
dose to 30mg twice daily to try to achieve better disease control.  One month later the cat 
showed signs of further improvement and the ACTH-stimulation test
a revealed an 
increased degree of steroid synthesis inhibition (Table 1, day 50).  The skin lesions on the 
neck and shoulders were almost completely resolved. Bilateral adrenalectomy was 
discussed with the owners as a way of controlling the hyperadrenocorticism in the long-
term but they were reluctant to have surgery performed and were concerned about the 
problems related to impaired wound-healing following laparotomy.  Follow-up 
examinations were taken over by the referring practice from this time.  
Six months after the start of treatment the cat developed an increased appetite for water 
and increased frequency of urination.  He was therefore referred back to the Queen 
Mother Hospital for investigation.  His appearance had not altered and his skin was still 
in good condition.  Abdominal palpation could identify only one kidney and abdominal 
radiographs showed that the left kidney was much smaller than the right.  Urine analysis 
revealed that yeast infection was present (urine culture yielded a growth of Candida 
albicans in excess of 10
6 organisms/ml) and blood work revealed a mild elevation in 
serum globulin (52.9g/l, range 26-51g/l) as well as hyperglycaemia (28.3mmol/l, range 
3.8-7mmol/l). The cat began treatment using the anti-fungal agent itraconazole
f (10mg/kg 
[4.5mg/lb] PO q 12 hrs.).  Several repeated urine analyses performed at the referring 
veterinary practice showed no change in the degree of Candida infection in the urinary 
tract.  After three weeks the drug was changed to fluconazole
g (50mg/kg [22.7mg/lb] PO 
q 12 hrs).  The fungal infection of the urinary tract proved refractory to treatment and 
renal function began to deteriorate.  Ten months after the start of therapy for 
hyperadrenocorticism the cat became anorexic and began to vomit.  He was found to be 
severely azotaemic (urea 80.5mmol/l, reference range 1.5-12mmol/l, creatinine 
1177µmol/l, reference range 90-200µmol/l) and did not respond to, or improve, following 
conventional fluid therapy.  The owners elected to euthanase the cat at this point and a 
post mortem examination was carried out. 
 
Post mortem examination identified disparity between the sizes of the kidneys with the 
left kidney appearing shrunken and irregular in outline (Fig – picture of kidneys) while 
the right kidney was enlarged.  The left kidney had marked destruction of the renal 
medulla, replaced by white purulent exudate, with cortical atrophy.  The cut surface of 
the right kidney appeared normal.  The adrenal glands were enlarged (1cm in diameter).  
A large pituitary mass was visible extending rostrally, running over the optic chiasm and 
protruding 3-4mm rostral to the optic chiasm (Fig – picture of brain).  Serial slicing of the 
fixed brain revealed the pituitary mass extending dorsally into the brain, forming a well-
demarcated, roughly spherical mass 12-15mm in diameter. 
 Histological examination of the left kidney showed prominent moderate multifocal 
cortical fibrosis and lymphoplasmacytic inflammation.  The Bowman’s capsule was 
thickened and there was mineralisation of the Bowman’s capsule and renal tubules.  
Moderate lymphoplasmacytic inflammation and mineralisation of renal tubular basement 
membranes was present also in the renal medulla. The renal pelvic cavity contained 
abundant fungal organisms (Candida species) which extended along the ureter.  The right 
kidney was similarly affected but to a much lesser degree.  Both adrenal glands had 
symmetrically enlarged cortices, reaching up to 5mm in depth.   
 
The pituitary mass was composed of polyhedral cells with a large pale stippled nucleus 
and moderate amounts of pale eosinophilic cytoplasm. There was mild anisokaryosis and 
occasional mitoses. The cells were divided by thin connective tissue septa and blood 
vessels, with a tendency to pallisade around blood vessels. Mild focal haemorrhage was 
present. The surrounding intensely eosinophilic cells were compressed by the mass. 
These features were considered typical of a chromophobe pituitary adenoma that had 
expanded dorsally into the overlying brain.   The diagnosis of pituitary-based 
hyperadrenocorticism was thus confirmed retrospectively. 
 
Feline hyperadrenocorticism is much more rare than the disease in dogs and differs also 
in the common presenting signs. As in dogs, most cases (81%) are pituitary-based and are 
caused by excessive ACTH release by neoplastic or hyperplastic ACTH-secreting cells
1.  
Cats frequently present with extreme skin fragility and skin infections. Severe skin 
problems are considered an indicator of poor prognosis. Polyuria and polydipsia, so often 
the main presenting sign in dogs, typically develop later in the disease and are due to the 
development of diabetes mellitus and an osmotic diuresis rather than to direct cortisol 
effects
2. Duesberg and Peterson
1 report an incidence of diabetes mellitus of 83% in cats 
with hyperadrenocorticism.  Since the time of their extensive review, several case studies 
and series have been published, including information detailing a further 19 cats, of 
which 13 were diabetic (68%)
3,4,5,6,7.  Although this figure is lower, it shows that diabetes 
mellitus is still much more common in cats with hyperadrenocorticism than in dogs 
where the incidence is around 5-10%
8.  
This case illustrates the problems in reaching a diagnosis of hyperadrenocorticism in cats 
using a conventional screening test.  ACTH-stimulation tests have been reported to be 
difficult to interpret in cats with systemic diseases, particularly diabetes mellitus or 
hyperthyroidism, because basal cortisol levels are typically higher and the response to 
stimulation tends to be more dramatic
9. This can lead to an over-diagnosis of 
hyperadrenocorticism in the cat.  In this case, the converse was true and the cat in this 
study failed to respond to ACTH up to the levels expected for a cat with 
hyperadrenocorticism (post-ACTH cortisol > 450nmol/l or >16µg/dL
1).  Previously 
described cases of hyperadrenocorticism have shown that only 51% of cats have an 
exaggerated response to ACTH, while 16% were borderline and the remainder were 
within the normal range quoted
1.   In two reported cases clinically suggestive of 
hyperadrenocorticism but where hypercortisolemia could not be documented, other 
steroid hormones, particularly progesterone, were measured and found to be elevated
4,10.  
Both of the cats in these reports had adrenal masses, however, and it is unlikely that the 
cat described here had a similar secretory profile.    The dexamethasone suppression test 
has also been used as a screening test in cats, although there is some contention about the 
dose required to achieve adrenal suppression. The recommended dose of dexamethasone 
varies between 0.01-0.1mg/kg with 15-20% of normal cats failing to suppress at a 
dexamethasone dose of 0.01mg/kg
11, 12.  Again, the specificity of this test is questionable 
in cases where there is concurrent disease.  Some authors suggest that a magnetic 
resonance scan to identify a possible pituitary tumour is a useful diagnostic test to run on 
cats with diabetes mellitus who present with insulin resistance
6 and report finding a 
pituitary mass in all four cats suspected of being hypercortisolemic.  The cat in this report 
did not present for insulin resistance and had not been recognised as having diabetes 
mellitus until referral to the Queen Mother Hospital but a magnetic resonance scan would 
have been a useful diagnostic test in this case and would have reinforced our tentative 
ante-mortem diagnosis. 
 Although mitotane (o,p’-DDD) has been the drug of choice for the treatment of canine 
hyperadrenocorticism for the past 10-15 years
13, in cats this drug has been found to give 
variable results
14,15,16,17.  
 
Two enzyme inhibitors have been used to control hyperadrenocorticism in cats.  One, 
ketoconazole, the primary use of which is for the treatment of mycotic disease, has been 
used with success in humans and dogs, but again has found to have unpredictable results 
in cats
18.  Willard et al.,
 18 were, however, measuring the plasma cortisol response to 
ketoconazole in healthy animals.  When a second group of cats with 
hyperadrenocorticism were treated, only two of five showed clinical improvement
19.  
Ketoconazole has the added disadvantage of being associated with a risk of side effects 
including nausea, vomiting, anorexia
18, elevated liver enzymes, jaundice
20 and 
thrombocytopenia
19.  Metyrapone is the second enzyme inhibitor to be used to treat cats 
with hyperadrenocorticism
21,22.  It is an inhibitor of 11-β-hydroxylase in the steroid 
synthesis pathway and thus interferes with cortisol and corticosterone (and consequently 
aldosterone) synthesis.  In one report of its use, metyrapone was documented to cause 
transient hypocortisolaemia followed by escape from the effects of enzyme inhibition, 
presumably mediated by an increase in plasma ACTH levels, although endogenous 
ACTH was not measured in this cat
21.  Its use is recommended as a pre-treatment prior to 
bilateral adrenalectomy, particularly in cases where there are large skin deficits and the 
prospects for effective wound healing are poor.  There is a problem with the availability 
of metyrapone, however, and for this case, we were unable to find a supplier. 
 
Trilostane is an inhibitor of 3β-17 hydroxysteroid dehydrogenase that blocks the 
synthesis of adrenal and gonadal steroid hormones.  It has been used for the treatment of 
hyperadrenocorticism in dogs with good results
23,24, but its use has not been reported in 
cats.  The subject of this report began medication with trilostane at a dose of 30mg once 
daily, though at 7.2kg a higher dose (60mg) would probably have been used in a canine 
patient.  Monitoring the response to treatment was complicated by the fact that the 
ACTH-stimulation test was within the normal range in the initial patient evaluation.  
Clinically, however, the cat improved and his skin lesions began to resolve.  A second improvement was noticed following the increase in dose to 30mg twice daily and at this 
point the refractory skin lesions over the cat’s neck and shoulders were closed for the first 
time.  Work in dogs has shown that trilostane has a relatively short duration of action 
(Neiger
25 ref) and it is possible that the same is true in cats and that more regular dosing 
is required for optimal control of clinical signs.  Trilostane caused no adverse effects in 
the subject of this study and the drug appeared to be tolerated well at both the original 
and higher doses.  
 
Funguria is infrequently reported in the cat, but is more common in cats where there is 
concurrent, immunosuppressive disease or other predisposing factors (e.g. indwelling 
urinary catheters)
26, 27.  The prognosis for spontaneous control of urinary fungal growth is 
good, so long as the primary disease is addressed and controlled
27.  In this case it appears 
that the urinary tract infection was never truly cleared and eventually led to renal 
insufficiency.  Earlier and more aggressive anti-fungal therapy may have improved the 
outcome though the prognosis for cats with renal fungal infection is poor
27.  That this 
secondary, opportunistic infection was so difficult to manage suggests that the cat’s 
hyperadrenocorticism was not adequately controlled by trilostane or that the diabetic 
control was inadequate.  Serial glucose curves showed that the cat’s glucose stayed below 
15mmol/l for 75% of the day and only became refractory to insulin treatment when there 
was a proven active urinary tract infection so it seems more likely that 
immunosuppression was secondary to hyperadrenocorticism
28.  Thus, although trilostane 
improved the condition of the cat, most notably the refractory skin infections and 
abscesses, it was not effective in reversing all of the metabolic consequences of 
hyperadrenocorticism at the dose used. 
 
Most authors agree that bilateral adrenalectomy is the treatment of choice for cats with 
hyperadrenocorticism as medical therapy has been found to be unrewarding
3,14,29.  
Surgery is, however, associated with a high incidence of intra-operative and post-
operative complications
29 though these are less frequently reported in cats than for 
dogs
30.  A significant number of problems center on the skin fragility and the incidence of 
wound breakdown and contamination
14. Though trilostane was not entirely successful in this case, it was able to improve the cat’s condition and allow the cutaneous wounds to 
heal. Trilostane may therefore be a useful adjunct to surgery for long-term management 
of feline hyperadrenocorticism and would provide an alternative to metyrapone. 
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Time from start of 
trilostane 
treatment 
(days) 
Cortisol  
pre-ACTH 
(nmol/l) 
Cortisol 60 
minutes post-
ACTH (nmol/l)  
Cortisol 120 
minutes post-
ACTH (nmol/l)  
0  197  307  354 
7  138  187  202 
21  168  199  240 
50*  135  150  175 
 
* Follows trilostane dose increase. 
Table 1: Results from sequential ACTH-stimulation tests pre and post-treatment with 
trilostane. 
  
 